Arcturus Therapeutics Holdings Inc. (ARCT) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Arcturus Therapeutics Holdings Inc. (ARCT) Bundle
Engineered for accuracy, our (ARCT) DCF Calculator allows you to evaluate Arcturus Therapeutics Holdings Inc. valuation using real-world financial data while providing complete flexibility to modify all essential parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.8 | 9.5 | 12.4 | 205.8 | 157.7 | 178.3 | 201.5 | 227.8 | 257.5 | 291.0 |
| Revenue Growth, % | 0 | -54.12 | 29.56 | 1564.82 | -23.33 | 13.03 | 13.03 | 13.03 | 13.03 | 13.03 |
| EBITDA | -24.4 | -70.6 | -201.7 | 13.7 | -24.2 | -110.1 | -124.4 | -140.6 | -158.9 | -179.6 |
| EBITDA, % | -117.47 | -740.56 | -1631.68 | 6.66 | -15.32 | -61.73 | -61.73 | -61.73 | -61.73 | -61.73 |
| Depreciation | .7 | .9 | 1.2 | 1.5 | 3.0 | 8.8 | 10.0 | 11.3 | 12.8 | 14.4 |
| Depreciation, % | 3.29 | 9.25 | 9.65 | 0.74214 | 1.87 | 4.96 | 4.96 | 4.96 | 4.96 | 4.96 |
| EBIT | -25.1 | -71.5 | -202.9 | 12.2 | -27.1 | -111.0 | -125.5 | -141.8 | -160.3 | -181.2 |
| EBIT, % | -120.76 | -749.81 | -1641.33 | 5.92 | -17.19 | -62.26 | -62.26 | -62.26 | -62.26 | -62.26 |
| Total Cash | 71.4 | 462.9 | 370.5 | 391.9 | 292.0 | 178.3 | 201.5 | 227.8 | 257.5 | 291.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.2 | 2.1 | 3.4 | 2.8 | 32.1 | 29.1 | 32.9 | 37.2 | 42.1 | 47.5 |
| Account Receivables, % | 10.48 | 22.28 | 27.24 | 1.34 | 20.33 | 16.33 | 16.33 | 16.33 | 16.33 | 16.33 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0.00000809127 | 0 | 0 | 0.000001618254 | 0.000001618254 | 0.000001618254 | 0.000001618254 | 0.000001618254 |
| Accounts Payable | 5.8 | 10.8 | 10.1 | 7.4 | 5.3 | 77.1 | 87.1 | 98.5 | 111.3 | 125.8 |
| Accounts Payable, % | 27.87 | 112.95 | 81.38 | 3.62 | 3.35 | 43.24 | 43.24 | 43.24 | 43.24 | 43.24 |
| Capital Expenditure | -.8 | -1.7 | -3.4 | -7.7 | -2.9 | -19.7 | -22.3 | -25.2 | -28.5 | -32.2 |
| Capital Expenditure, % | -3.93 | -18.26 | -27.56 | -3.75 | -1.84 | -11.07 | -11.07 | -11.07 | -11.07 | -11.07 |
| Tax Rate, % | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 | -6.58 |
| EBITAT | -24.8 | -70.7 | -206.0 | 10.7 | -28.9 | -107.8 | -121.9 | -137.8 | -155.7 | -176.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -21.4 | -66.6 | -210.2 | 2.5 | -60.3 | -44.0 | -127.9 | -144.6 | -163.4 | -184.7 |
| WACC, % | 16.13 | 16.13 | 16.13 | 16.1 | 16.13 | 16.12 | 16.12 | 16.12 | 16.12 | 16.12 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -402.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -192 | |||||||||
| Terminal Value | -1,585 | |||||||||
| Present Terminal Value | -750 | |||||||||
| Enterprise Value | -1,153 | |||||||||
| Net Debt | -262 | |||||||||
| Equity Value | -891 | |||||||||
| Diluted Shares Outstanding, MM | 27 | |||||||||
| Equity Value Per Share | -33.47 |
What You Will Get
- Real ARCT Financial Data: Pre-filled with Arcturus Therapeutics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Arcturus Therapeutics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive Data: Arcturus Therapeutics' historical financial statements and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Results: View Arcturus’ intrinsic value recalibrated instantly.
- Intuitive Visual Outputs: Dashboard charts showcase valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing Arcturus Therapeutics Holdings Inc. (ARCT) preloaded data.
- 2. Adjust Key Inputs: Modify essential assumptions such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to understand different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to bolster your strategic decisions.
Why Choose Arcturus Therapeutics Holdings Inc. (ARCT)?
- Innovative Solutions: Cutting-edge technology in RNA medicines tailored for unmet medical needs.
- Robust Pipeline: A diverse range of therapeutic candidates targeting various diseases.
- Expert Team: Led by industry veterans with extensive experience in biotech and pharmaceuticals.
- Strong Partnerships: Collaborations with leading organizations to enhance research and development.
- Commitment to Quality: Adherence to the highest standards in manufacturing and clinical trials.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them using real-world case studies.
- Researchers: Integrate advanced therapeutic models into academic projects or studies.
- Investors: Evaluate your investment strategies and analyze valuation outcomes for Arcturus Therapeutics Holdings Inc. (ARCT).
- Market Analysts: Enhance your analysis with a tailored, ready-to-use financial model specific to the biotech sector.
- Healthcare Entrepreneurs: Understand the methodologies used to assess large biotech firms like Arcturus Therapeutics Holdings Inc. (ARCT).
What the Template Contains
- Pre-Filled DCF Model: Arcturus Therapeutics' financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Arcturus Therapeutics' profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.